Uveitis Pipeline Drugs Assessment Market: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

$ PRICE - $ 2,000.00$ 6,000.00

Uveitis Pipeline Drugs Assessment Market: By Route Of Administration (Oral, Topical, Parenteral), By Trial Phase (Preclinical Trials, Phase 1, Phase 2, Phase 3), and Geography  

 

$ PRICE - $ 2,000.00$ 6,000.00
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,000.00
FacebookTwitterLinkedinEmail

Report

Description

Uveitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Uveitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Uveitis disease pipeline drugs development. This report studies the dynamics of the Uveitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Uveitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development. Uveitis refers to the inflammation of uvea which is the middle layer of the eyeball. This may occur from either infectious or non-infectious cause. Retina is the sensitive part of the eye, uvea supplies blood to retina. Usually, uveitis is not serious, but if it is untreated may lead to vision loss. Symptoms may include, redness of eye, pain, dark floating spots on vision, blurred vision and others. There are many possible causes for uveitis including, entry of toxic substances and autoimmune diseases also lead to uveitis. Diagnosis is through the normal eye examination and treatment is given for the underlying diseases if any. Usually, corticosteroid eye drops are suggested to fight against the inflammation. Further, if not work oral or parenteral drugs may be given.

Uveitis Pipeline Drugs Assessment Market

MARKET SUMMARY
-
x%
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– x%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Uveitis Pipeline Drugs Assessment Market

  • The report on global uveitis disease pipeline drugs assessment market gives historical, current and future market sizes (US$ Mn) based on route of administration, by trial phase and regions.
  • uveitis disease pipeline drugs assessment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Apitope International
  • pSivida
  • Charlesson, LLC.
  • Enzo Biochem, Inc.
  • Mitotech SA
  • Galapagos NV
Uveitis Pipeline Drugs Assessment Market

Drivers And Restraints

Various advanced technologies in the molecular and cellular levels are driving the development of uveitis pipeline drugs. Researchers and manufacturing companies are using the various promising targets for uveitis treatment. Targeted therapy found to be more effective in treatment. Other possible targets are to slow the progression of the disease and relieving the symptoms. Many of the companies are collaborating in development of novel therapies for the treatment of uveitis.


North-America got significant share

Uveitis Pipeline Drugs Assessment Market

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In July 2017, Galapagos announced a new phase II study investigating filgotinib in non-infectious uveitis, being led by filgotinib collaboration partner Gilead Sciences. The phase II study will be a multi-center, randomized, double-masked, placebo-controlled study to assess the safety and efficacy of filgotinib in adult patients with active, non-infectious uveitis.
  • In June 2017, pSivida Corp. announced the Company’s second Phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved the trial’s primary endpoint and results found to be positive.

Key

Key Features of the Report

Uveitis Pipeline Drugs Assessment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Apitope International (Ukraine)
  • pSivida (U.S.)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Charlesson, LLC. (U.S.)
  • Enzo Biochem, Inc. (U.S.)
  • Mitotech SA (Luxembourg)
  • EyeGate Pharmaceuticals Inc (U.S.)
  • Galapagos NV (Belgium)
  • Others

Description

Uveitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Uveitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Uveitis disease pipeline drugs development. This report studies the dynamics of the Uveitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Uveitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development. Uveitis refers to the inflammation of uvea which is the middle layer of the eyeball. This may occur from either infectious or non-infectious cause. Retina is the sensitive part of the eye, uvea supplies blood to retina. Usually, uveitis is not serious, but if it is untreated may lead to vision loss. Symptoms may include, redness of eye, pain, dark floating spots on vision, blurred vision and others. There are many possible causes for uveitis including, entry of toxic substances and autoimmune diseases also lead to uveitis. Diagnosis is through the normal eye examination and treatment is given for the underlying diseases if any. Usually, corticosteroid eye drops are suggested to fight against the inflammation. Further, if not work oral or parenteral drugs may be given.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX